Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Accumulated Expenses: 2012-2024

Historic Other Accumulated Expenses for Iovance Biotherapeutics (IOVA) over the last 2 years, with Mar 2024 value amounting to $4.0 million.

  • Iovance Biotherapeutics' Other Accumulated Expenses fell 7.25% to $4.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $4.0 million, marking a year-over-year decrease of 7.25%. This contributed to the annual value of $6.6 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q1 2024, Iovance Biotherapeutics' Other Accumulated Expenses is $4.0 million, which was down 39.65% from $6.6 million recorded in Q4 2023.
  • In the past 5 years, Iovance Biotherapeutics' Other Accumulated Expenses registered a high of $6.6 million during Q4 2023, and its lowest value of $4.0 million during Q1 2024.
  • Over the past 2 years, Iovance Biotherapeutics' median Other Accumulated Expenses value was $4.3 million (recorded in 2023), while the average stood at $4.7 million.
  • Data for Iovance Biotherapeutics' Other Accumulated Expenses shows a maximum YoY decreased of 7.25% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Iovance Biotherapeutics' Other Accumulated Expenses stood at $6.6 million in 2023, then decreased by 7.25% to $4.0 million in 2024.
  • Its Other Accumulated Expenses was $4.0 million in Q1 2024, compared to $6.6 million in Q4 2023 and $4.3 million in Q3 2023.